Funding for this research was provided by:
Chemocentryx
Article History
Received: 23 October 2022
Accepted: 23 February 2023
First Online: 10 April 2023
Declarations
:
: LA reports consultant fees from ChemoCentryx, a wholly-owned subsidiary of Amgen, Inc. NK and RS have no conflicts of interest to report.
: The case study was conducted ethically in accordance with the Declaration of Helsinki.
: This study was performed according to the Declaration of Helsinki. No animals were involved in this study.
: The patient described in this manuscript provided written informed consent.